Novartis Oncology Cancer Clinical Trials
The Pipeline of Novartis Oncology
Targeting multiple tumor types
The Novartis Oncology pipeline includes compounds in all phases of development, starting with preclinical studies in tumor cell line and animal models through large Phase III randomized trials.
Everolimus is a particularly promising oral kinase inhibitor now being investigated in Phase I to III clinical trials in multiple tumor types, including neuroendocrine tumors, renal cell carcinoma, and colorectal, lung, and breast cancers.
A Pipeline That Spans All Phases
Click on the compound name below to learn more.
2
3
4
5
6
7
8
9
10
a
b
c
d
e
f
g
h
Non-Transfusion-Dependent Thalassemia
Non small cell lung cancer
Acute myeloid leukemia
Neuroendocrine tumor
Tuberous sclerosis complex in subependymal giant cell astrocytoma and angiomyolipomas
Gastrointestinal stromal tumor
Chronic myeloid leukemia
Hepatocellular carcinoma
Myelodysplastic syndromes
INC280 (also known as INCB028060) is licensed from Incyte Corp.
MEK162 (also known as ARRY-162) is licensed from Array BioPharma Inc.
Also known as LBH589
Also known as TKI258
Subject to an agreement between Novartis Oncology and Xoma.
ASA404 (vadimezan, formerly known as AS1404, DMXAA) is licensed from Antisoma.
INC424, also known as INCB018424, is being developed collaboratively by Incyte and Novartis AG. Novartis AG has licensed the rights to INC424 outside the United States. Incyte maintains the rights within the United States.
Also known as SOM230
Exploratory in solid tumors – BEZ235, AUY922, BKM120, LCL161, HSP990, BGJ398, LDE225, INC280*** and MEK162‡.
Exploratory in hematological malignancies – BHQ880
*ASA404 (vadimezan, formerly known as AS1404, DMXAA) is licensed from Antisoma.
**Also known as TKI258.
***INC280 (also known as INCB028060) is licensed from Incyte Corp.
†Also known as LBH589.
‡MEK162 (also known as ARRY–162) is licensed from Array BioPharma Inc.
§Subject to an agreement between Novartis Oncology and Xoma.
˜INC424, also known as INCB018424, is being developed collaboratively by Incyte and Novartis AG. Novartis AG has licensed the rights to INC424 outside the United States. Incyte maintains the rights within the United States.
All compounds or uses are investigational. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.
SEARCH OUR WEBSITES
PRODUCTS
At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.
CAREERS AT NOVARTIS
Our success depends entirely on the creativity, performance and achievement of our associates at all levels.
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
CLINICAL TRIALS
Our Clinical Trials are crucial in determining the safety and efficacy of new drugs and treatments.